DAWN Q2 2021 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$49,000

Operating Income

-$15M

Net Income

-$14M

EPS (Diluted)

$-0.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$317M

Total Liabilities

$5M

Stockholders' Equity

$312M

Cash & Equivalents

$310M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$49,000	-$46,000	-6.5%
Operating Income	-$15M	-$2M	-568.6%
Net Income	-$14M	-$2M	-711.5%